Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/29924
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPedrini, Steve-
dc.contributor.authorChatterjee, Pratishtha-
dc.contributor.authorNakamura, Akinori-
dc.contributor.authorTegg, Michelle-
dc.contributor.authorHone, Eugene-
dc.contributor.authorRainey-Smith, Stephanie R-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorAmes, David-
dc.contributor.authorKaneko, Naoki-
dc.contributor.authorGardener, Sam L-
dc.contributor.authorTaddei, Kevin-
dc.contributor.authorFernando, Binosha-
dc.contributor.authorMartins, Ian-
dc.contributor.authorBharadwaj, Prashant-
dc.contributor.authorSohrabi, Hamid R-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorBrown, Belinda-
dc.contributor.authorMartins, Ralph N-
dc.date2022-
dc.date.accessioned2022-06-22T06:40:43Z-
dc.date.available2022-06-22T06:40:43Z-
dc.date.issued2022-03-28-
dc.identifier.citationFrontiers in Aging Neuroscience 2022; 14: 771214en
dc.identifier.issn1663-4365
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/29924-
dc.description.abstractPrevious studies have indicated that physical activity may be beneficial in reducing the risk for Alzheimer's disease (AD), although the underlying mechanisms are not fully understood. The goal of this study was to evaluate the relationship between habitual physical activity levels and brain amyloid deposition and AD-related blood biomarkers (i.e., measured using a novel high-performance mass spectrometry-based assay), in apolipoprotein E (APOE) ε4 carriers and noncarriers. We evaluated 143 cognitively normal older adults, all of whom had brain amyloid deposition assessed using positron emission tomography and had their physical activity levels measured using the International Physical Activity Questionnaire (IPAQ). We observed an inverse correlation between brain amyloidosis and plasma beta-amyloid (Aβ)1-42 but found no association between brain amyloid and plasma Aβ1-40 and amyloid precursor protein (APP)669-711. Additionally, higher levels of physical activity were associated with lower plasma Aβ1-40, Aβ1-42, and APP669-711 levels in APOE ε4 noncarriers. The ratios of Aβ1-40/Aβ1-42 and APP669-711/Aβ1-42, which have been associated with higher brain amyloidosis in previous studies, differed between APOE ε4 carriers and non-carriers. Taken together, these data indicate a complex relationship between physical activity and brain amyloid deposition and potential blood-based AD biomarkers in cognitively normal older adults. In addition, the role of APOE ε4 is still unclear, and more studies are necessary to bring further clarification.en
dc.language.isoeng
dc.subjectAPOE genotypeen
dc.subjectAlzheimer's diseaseen
dc.subjectamyloiden
dc.subjectbiomarkersen
dc.subjectphysical activityen
dc.titleThe Association Between Alzheimer's Disease-Related Markers and Physical Activity in Cognitively Normal Older Adults.en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in Aging Neuroscienceen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.affiliationDepartment of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australiaen
dc.identifier.affiliationCentre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australiaen
dc.identifier.affiliationSchool of Medical Sciences, Sarich Neuroscience Research Institute, Edith Cowan University, Nedlands, WA, Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St George's Hospital, University of Melbourne, Kew, VIC, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, VIC, Australiaen
dc.identifier.affiliationCenter for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japanen
dc.identifier.affiliationDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United Statesen
dc.identifier.affiliationKoichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, Kyoto, Japan..en
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35418852/en
dc.identifier.doi10.3389/fnagi.2022.771214en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3910-2453en
dc.identifier.orcid0000-0002-8051-0558en
dc.identifier.orcid0000-0003-3072-7940en
dc.identifier.pubmedid35418852
local.name.researcherDoré, Vincent
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

48
checked on Mar 10, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.